Business
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
Conference call and webcast on Monday, June 23, 2025 at 8:00 am EDTBALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a conference call and webcast to discuss regulatory updates for the Company’s nomlabofusp clinical development program for the treatment of Friedreich’s Ataxia on Monday, June 23, 2025 a
About this update from Larimar Therapeutics, Inc.
[{"type":"image","alt":"Larimar Therapeutics","displaySize":"","headline":null,"caption":"Larimar Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":107,"url":"https://media.zenfs.com/en/globenewswire.com/59a0cb6afa06818e6bf352c70da11d95"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1uUrf9fLQ_8GcyV6eEAsEw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/59a0cb6afa06818e6bf352c70da11d95","width":300,"height":107}},"lazy":false},{"type":"text","content":"Conference call and webcast on Monday, June 23, 2025 at 8:00 am EDT","length":67,"tagName":"p"},{"type":"text","content":"BALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a conference call and webcast to discuss regulatory updates for the Company’s nomlabofusp clinical development program for the treatment of Friedreich’s Ataxia on Monday, June 23, 2025 at 8:00 am EDT.","length":447,"tagName":"p"},{"type":"text","content":"Conference Call and Webcast DetailsTo access the webcast on Monday, June 23, 2025 at 8:00 am EDT, please visit this link to the event. To participate by phone, please dial 1-877-407-9716 (domestic) or 1-201-493-6779 (international) and refer to conference ID 13754491 or click on this link and request a return call. Following the live event, an archived webcast will be available on the “Events & Presentations” page of the Larimar website.","length":456,"tagName":"p"},{"type":"text","content":"About Larimar TherapeuticsLarimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.","length":553,"tagName":"p"},{"type":"text","content":"Forward-Looking StatementsThis press release contains forward-looking statements that are base...